Comorbid Affective and Substance Use Disorders of Medicaid/Medicare Beneficiaries at an Opioid Treatment Program Serving Small Urban and Rural Communities

Jamey J. Lister 1,2,*, Guijin Lee 2, Jennifer D. Ellis 2,3, Emily Pasman 2, Elizabeth Agius 2 and Stella M. Resko 2,4

1 Rutgers University School of Social Work, New Brunswick, NJ, United States, 2 Wayne State University School of Social Work, Detroit, MI, United States, 3 Johns Hopkins School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, MD, United States, 4 Wayne State University Merrill Palmer Skillman Institute, Detroit, MI, United States

Objectives: Identify rates and correlates of comorbid affective and substance use disorders among an understudied population, Medicaid/Medicare beneficiaries receiving care at an opioid treatment program serving patients from small urban and rural areas. Examine whether past-year non-medical opioid use status differentiates comorbidity status.

Methods: A cross-sectional, venue-based design was used to recruit a convenience sample of patients treated with methadone for opioid use disorder. Measures were assessed across three domains: (1) demographic characteristics, (2) opioid use characteristics, and (3) comorbid disorders. Brief validated screeners categorized probable comorbid disorders. Bivariate analyses examined correlates of comorbid disorders and determined variable selection for multivariable analyses.

Results: In this sample (N = 210; mean age = 38.5 years; female = 62.2%; Non-Hispanic White race/ethnicity = 86.1%), comorbid disorders were common. Rates were as follows: current anxiety (48.1%), depression (41.1%), and PTSD (33.7%), and past-year stimulant (27.6%), marijuana (19.0%), alcohol (14.9%), and sedative (7.6%). In bivariate analyses, past-year non-medical opioid use and a greater accumulation of opioid use consequences were associated with most disorders. When including demographic and opioid use characteristics in multivariable analyses, past-year non-medical opioid use was associated with anxiety, PTSD, stimulant use disorder, and sedative use disorder.

Conclusions: Few studies have investigated comorbid disorders among this understudied population. This analysis highlights a high burden, especially for affective disorders. Our findings demonstrate that routine, ongoing assessment of non-medical...
INTRODUCTION

People receiving methadone treatment for opioid use disorder (OUD) often have multiple morbidities. Studies estimate that more than 80% of patients in methadone treatment have at least one comorbid affective or substance use disorder (1, 2). Among people with OUD, past-year comorbidity rates range from 13 to 26% for alcohol, cannabis, cocaine, and sedative use disorder, and 64% have at least one mental health disorder (3). Comorbid disorders, especially other substance use disorders, are associated with worse treatment outcomes (1, 4). Comorbid depressive, trauma-related, and anxiety disorders, while less consistent risk factors for worse treatment outcomes (1, 5, 6), necessitate assessment and integrated approaches. These are especially urgent considering people with comorbid substance use and affective disorders are at high risk for fatal overdose people compared to those without comorbidity disorders (7). While facilities providing methadone in the United States, formally called opioid treatment programs (OTPs), are required to provide substance use counseling or behavioral therapies in conjunction with medication treatment (8), there is no specific requirement for those counseling services to address co-occurring affective disorders (9).

Assessment and monitoring of methadone treatment processes and outcomes are required by federal guidelines for OTPs; and these guidelines recommend assessment of comorbid disorders (10). The Substance Abuse and Mental Health Services Administration (SAMHSA) advocates for the use of validated screening and assessment tools in their Treatment Improvement Protocol series on substance use and co-occurring disorders (11). However, because the use of validated tools is not a formal requirement for OTP intake, non-validated instruments developed by local and state treatment authorities are commonly used (12). Furthermore, some patients may not report psychiatric distress early in treatment (i.e., during intake assessment), but may experience symptoms that begin after induction or stabilization to methadone. Therefore, quickly screening patients at regular intervals throughout treatment may identify the need for integrated care approaches to address comorbid affective and substance use disorders. Furthermore, identifying innovative yet feasible strategies, such as low-burden screening, represents an approach that may improve care and be better adopted than resource-intensive strategies not well suited for the complexity of the existing addiction treatment system.

Screening for comorbid affective and substance use disorders in small urban and rural communities may be particularly important. People with comorbid disorders living in these settings often experience considerable challenges when trying to access care that is located outside of their OTP, due primarily to travel and transportation barriers, whether personal or public (13, 14). Research has demonstrated that OTP patients referred to care offsite are at risk for poor treatment attendance and retention (15, 16). Thus, the use of validated screening measures, which assess comorbid disorder symptoms and non-medical opioid use patterns during treatment, have the potential to improve co-located care coordination at OTPs serving small urban and rural patient populations, and address a largely unmet comorbid disorder burden.

To date, investigations gathering primary data on comorbid disorders among patients in methadone treatment are restricted mainly to samples from large urban areas, due to a scarcity of OTPs in small urban and rural areas (17, 18) and relatively few patients traveling to large urban areas from smaller surrounding communities (13). Furthermore, primary data studies of patients being treated with methadone rarely constrain the sample to target the needs of publicly-insured populations, despite disproportionate odds for methadone services to be paid by public funds (19), and higher odds of opioid overdose among Medicaid/Medicare beneficiaries (20).

This study represents the first primary data collection addressing comorbid affective and substance use disorders among a sample of Medicaid/Medicare beneficiary patients from small urban and rural communities receiving methadone treatment. Our aims were as follows. We sought to identify rates of probable comorbid affective and substance use disorders using validated screening tools; examine demographic and opioid use characteristic correlates of comorbid disorders; and investigate whether past-year non-medical opioid use status was a significant differentiator of comorbid disorder status in multivariable analyses when including other key characteristics. We hypothesized that a high rate of comorbid disorders would be observed, with stronger correlations for opioid use characteristic variables and comorbid disorders than for demographic characteristics and comorbid disorders. Last, we hypothesized that past-year non-medical opioid use status would be the most consistent correlate of comorbid disorders in multivariable analyses.

MATERIALS AND METHODS

Setting and Procedure

A venue-based recruitment strategy was used to recruit patients receiving methadone for OUD at an OTP situated in a medically underserved area of a small urban county (Rural Urban Continuum Code/RUCC = 3) (21). The clinic’s catchment area extends to several surrounding rural counties (RUCCs = 4–7) (21) south of the clinic, and rural census tracts, using Federal...
Office of Rural Health Policy definitions for rural zip codes in urban counties (22), situated north and west of the clinic.

Data collection occurred over 3 weeks in December 2019 (23), with 267 patients enrolled in the parent study. In the weeks before data collection, OTP staff informed patients of the study and distributed recruitment materials. Research staff were onsite for data collection three varied days of each week. A convenience sample of patients completed self-administered computer-based surveys in a private room located at the clinic. Research staff obtained informed consent (using an information sheet approved with a documentation waiver), assisted with surveys as needed (e.g., due to difficulties with reading or technology), and provided compensation ($25 gift card to a large shopping outlet) for completing surveys.

For this analysis, we focus on the subset of patients who had their treatment funded by Medicaid or Medicare. All patients were eligible for this analysis, regardless of when they started treatment. Thus, the sample includes patients new to treatment, as well as those who were engaged with the clinic for long-term care. We focus on the analytic sample of Medicaid/Medicare beneficiaries receiving methadone treatment1 because preliminary analyses demonstrated higher rates of comorbid disorders among Medicaid/Medicare beneficiaries compared to patients reporting private health insurance or self-pay. This is consistent with literature showing a greater comorbidity burden among publicly-insured populations with OUD (24). Additionally, we were not adequately powered to compare differences based on payment type in the analytic sample (N = 210; Medicaid: n = 196, 93.3%; Medicare: n = 14, 6.7%). All study procedures were approved by the Wayne State University Institutional Review Board.

**Measures**

Surveys assessed measures across three domains: demographic characteristics, opioid use characteristics, and comorbid affective and substance use disorder screening measures.

**Demographic Characteristics**

Patients provided demographic information, including their current age (years), geography (zip code of residence), gender identity (male, female, other), race/ethnicity (Arabic/Middle Eastern, Hispanic/Latino, Non-Hispanic African American, Non-Hispanic Asian, Non-Hispanic Native American, Non-Hispanic Native Hawaiian, Non-Hispanic White, Non-Hispanic more than one race), educational attainment (earned high school diploma or GED, had not earned a high school diploma or GED), and their public health insurance type (Medicaid, Medicare). To measure rural-urban community of residence, we used the Goldsmith Modification (25), a technique outlined by the Federal Office of Rural Health Policy to categorize rurality using patient zip codes at the county (RUCCs 4–9) and federally-defined rural census tracts (i.e., rural zip codes embedded within urban counties). Though the gender item included a non-binary response option, no patients reported a gender aside from male or female. Because the sample was predominantly Non-Hispanic White and other race/ethnicity groups were smaller (<5%), race/ethnicity was dichotomized (Non-Hispanic White, other race/ethnicity) to ensure adequate statistical power to detect group differences.

**Opioid Use Characteristics**

Patients answered questions about five opioid use characteristics. These brief measures were selected due to high clinical feasibility and reduced patient burden. First, patients were asked about non-medical opioid use in the past year. Past-year non-medical opioid use was then compared with the date the patient started their current treatment episode to indicate the absence of past-year use (reference category) or occurrence of past-year use before starting treatment or while in treatment (coded as 1 and 2). Patients reported their history of fentanyl use, whether intentional or unintentional (dichotomous: no history, history), as well as their preference for injection drug use (dichotomous: not preferred, preferred). Patients also completed an adapted version of the Heroin Use Consequence scale (26) to assess lifetime opioid use consequences. Though the original HUC scale focuses on consequences of heroin use specifically, in the current study patients were asked to consider their use of all opioids except those used as directed by a doctor. Education-related consequences (three items from the original 20-item scale), that were among the least endorsed in the scale development study (26), were excluded to reduce time burden. This resulted in a total of 17 items that were summed. Last, we assessed whether patients had been in treatment during the current episode for 1 year or more.

**Comorbid Affective and Substance Use Disorder Screening Measures**

Validated screens were administered for seven comorbid disorders. Established cut scores were used to categorize patients as having probable comorbid disorders (i.e., positive screens). Three screens assessed probable comorbid affective disorders, including depression (Patient Health Questionnaire-2; PHQ-2, a score of three or greater during the past 2 weeks was interpreted as a positive screen) (27), anxiety (Generalized Anxiety Disorder 2-Item Scale; GAD-2, a score of three or greater during the past 2 weeks was interpreted as a positive screen) (27), and PTSD (Primary Care PTSD Screen for DSM-5; PC-PTSD-5, a score of four or greater during the past month was interpreted as a positive screen) (28). Four screens assessed probable comorbid substance use disorders during the past year, including stimulants (Stimulant Severity of Dependence Scale, a score of three or greater was used) (29), cannabis (Cannabis Severity of Dependence scale, a score of three or greater was used) (30), alcohol (AUDIT-C, for women, a score of three or greater was used and for men a score of four or greater was used to identify patients with hazardous drinking or active alcohol use disorder) (31), and sedatives (Sedative Severity of Dependence Scale, a score of six or greater was used) (29).

---

1Forty cases were excluded when treatment was funded by private health insurance (n = 34) or self-pay (n = 6). An additional 17 cases were removed for missing data on key study variables (past-year non-medical opioid use, current methadone status).
Data Analysis
We analyzed data using SPSS version 27 (IBM Corp., 2017). After the removal of patients from the analytic sample (described in Settings and Procedure), cases from variables with small amounts of missing data (1–2 cases) were removed using listwise deletion by default. Little's MCAR test indicated data were missing completely at random \[ \chi^2 (158) = 169.586, p = 0.250 \] (32). Measures of central tendency and distribution were calculated for all variables. Group (t-tests, chi-square, one-way ANOVA) and correlation analyses (Kendall's Tau-b) explored differences and associations between demographic characteristics, opioid use characteristics, and comorbid disorder screening measures. Adjusted standardized residuals (ASRs) were used to estimate low (≤-2) and high values (>2), in line with Haberman's rule of thumb (33), in bivariate analyses of past-year non-medical opioid use status (a three-level categorical variable). We then conducted binomial logistic regressions to examine whether past-year non-medical opioid use status remained a significant differentiator of probable comorbid disorders after including demographic and opioid use characteristics that demonstrated directional \( p < 0.20 \) associations in bivariate analyses. Since the comorbid disorder screening measures for alcohol and depression did not differ by past-year non-medical opioid use status in bivariate analyses, they were not included alongside the other five comorbid disorder screening measures as dependent variables in multivariable regression analyses. Due to collinearity with past-year non-medical opioid misuse status, time in treatment was excluded from multivariable analyses.

RESULTS
Sample Description
Table 1 displays descriptive information about the analytic sample for demographic characteristics, opioid use characteristics, and rates of comorbid disorders.

Group Differences for Comorbid Disorders by Demographic and Opioid Use Characteristics
Table 2 presents bivariate relationships between demographic and opioid use characteristics and each of the seven comorbid disorder screening measures. Younger age was associated with PTSD (\( p < 0.001 \)), and lower educational attainment was associated with sedative use disorder (\( p < 0.05 \)). Other demographic characteristics met bivariate determination (\( p < 0.20 \)) for multivariable regression analyses, including the negative relationships between female gender and marijuana use disorder and the positive relationship between female gender and anxiety and alcohol use disorder, and the positive relationship between living in a rural community and marijuana use disorder. The Non-Hispanic White race/ethnicity variable was excluded from the sedative use disorder model in bivariate and multivariable analyses due to perfect separation (i.e., 100% of the patients with sedative use disorder reported non-Hispanic White race/ethnicity).

With regard to opioid use characteristics, a greater lifetime accumulation of opioid use consequences was positively associated with PTSD (\( p < 0.001 \)), stimulant use disorder (\( p < 0.001 \)), anxiety (\( p < 0.01 \)), sedative use disorder (\( p < 0.01 \)), and met bivariate determination (\( p < 0.20 \)) for marijuana use disorder and depression. A history of fentanyl use was associated with PTSD (\( p < 0.01 \)), sedative use disorder (\( p < 0.01 \)), and stimulant use disorder (\( p < 0.05 \)), and met bivariate determination (\( p < 0.20 \)) for past-year non-medical opioid use status. A history of fentanyl use was associated with PTSD (\( p < 0.001 \)), anxiety (\( p < 0.01 \)), sedative use disorder (\( p < 0.01 \)), and met bivariate determination (\( p < 0.20 \)) for past-year non-medical opioid use status.

Group Differences for Comorbid Disorders by Past-Year Non-Medical Opioid Use Status
Table 3 displays bivariate analyses for comorbid disorder screening measures by past-year non-medical opioid use status. Five of the seven comorbid disorders, including anxiety (\( p < 0.05 \)), PTSD (\( p < 0.001 \)), marijuana use disorder (\( p < 0.05 \)), stimulant use disorder (\( p < 0.001 \)), and sedative use disorder (\( p < 0.01 \)) differed significantly by past-year non-medical opioid use status, whereas depression and alcohol use disorder were unrelated. High and/or low ASR values were examined for the same five comorbid disorders among the three past-year non-medical opioid use status groups. Specifically, patients reporting no past-year non-medical opioid use had low levels (ASR ≤-2) of anxiety, PTSD, marijuana use disorder, stimulant use disorder, and sedative use disorder. In contrast, patients reporting past-year non-medical opioid use that occurred before treatment had

| TABLE 1 | Sample characteristics (N = 210). |
|---------|-----------------|---------|---------|
|         | n               | Valid % | M (SD)  |
| Demographic characteristics | | | |
| Age (in years) | 38.53 (10.13) | | |
| Female gender | 130 | 62.2 | | |
| High school degree or equivalent | 158 | 75.2 | | |
| Non-Hispanic White race/ethnicity | 180 | 86.1 | | |
| Rural community | 29 | 14.4 | | |
| Opioid use characteristics | | | |
| Fentanyl use | 129 | 61.7 | | |
| Injection preference | 83 | 39.5 | | |
| Opioid use consequences | | | 10.25 (4.49) |
| Time in treatment > 1 year | 169 | 71.6 | | |
| Comorbid disorders | | | |
| Depression | 85 | 41.1 | | |
| Anxiety | 100 | 48.1 | | |
| Alcohol | 31 | 14.9 | | |
| Marijuana | 40 | 19.0 | | |
| Stimulant | 58 | 27.6 | | |
| Sedative | 16 | 7.6 | | |

Age range, 22–72 years. Frequencies for other race/ethnicity groups: Non-Hispanic more than one race (n = 10, 4.8%), Non-Hispanic African American or Black (n = 8, 3.8%), Non-Hispanic Asian American (n = 2, 1.0%), and Non-Hispanic Native American or Alaska Native (n = 2, 1.0%). Reference groups (in parentheses) were as follows: gender (male), education (less than HS/GED), race (other race/ethnicity), community (non-rural), fentanyl use (no history), and injection opioid use (no history).
high levels (ASR ≥2) of PTSD, marijuana use disorder, and stimulant use disorder, while patients reporting past-year non-medical opioid use while in treatment had high levels (ASR ≥2) of stimulant use disorder and sedative disorder.

### Multivariable Regressions of Comorbid Disorders

Five separate multivariable regression models were conducted (see Table 4). Four models were significant (PTSD: \( p < 0.01 \); stimulant use disorder: \( p < 0.001 \); sedative use disorder: \( p < 0.001 \); anxiety: \( p < 0.01 \), and one was not (marijuana use disorder: \( p > 0.05 \)).

Past-year non-medical opioid use before treatment was significant in all three models (PTSD: \( p < 0.01 \); stimulant: \( p < 0.01 \); sedative: \( p < 0.05 \)). Past-year non-medical opioid use while in treatment was significant in two models (stimulant: \( p < 0.001 \); sedative: \( p < 0.05 \)). A greater number of opioid use consequences was significant in two models (PTSD: \( p < 0.01 \); stimulant: \( p < 0.05 \)). Other significant variables included younger age in the PTSD model (\( p < 0.01 \)), lower educational attainment in the stimulant use model (\( p < 0.05 \)), and female gender in the anxiety model (\( p < 0.05 \)). Fentanyl use, injection drug use preference, Non-Hispanic White race/ethnicity, and rural community were not significant in any models.

### DISCUSSION

This study identified rates and correlates of comorbid disorders among Medicaid/Medicare beneficiary patients from small urban and rural communities receiving methadone treatment for OUD. This analysis highlights a high comorbidity burden, especially for affective disorders. Our findings also reveal a consistent role for past-year non-medical opioid use to detect patients in greater need of integrated care for comorbid disorders. To date, few studies have examined comorbid affective and substance use disorders among this understudied population.

Comorbid disorders were common in this sample, especially for affective disorders, with rates of 48, 41, and 34%, for anxiety, depression, and PTSD, respectively. Consistent with predictions, rates were lower for comorbid substance use disorders, though 28% of patients still screened positive for stimulant use disorder. When analyzing differences by past-year non-medical opioid use status, considerably higher rates for all seven comorbid disorders were demonstrated among patients reporting use before and/or while in treatment. As illustration, within the sub-sample of patients reporting past-year use that occurred before treatment, or while in treatment, 62 and 57%, respectively, screened positive compared to 39% of patients reporting no past-year use. Similarly, 62% of patients reporting past-year use while in treatment screened positive for PTSD, compared to 39% reporting past-year before treatment, and 23% reporting no past-year use. The difference was starkest for stimulant use disorder, where 46% (past-year use while in treatment) and 45% (past-year use before treatment), respectively, screened positive, compared to only 12% of patients reporting no past-year use. For all seven disorders assessed, patients reporting no past-year use had lower rates than either group reporting past-year use, regardless of whether it occurred before or while in treatment. Consistent with hypotheses, these relationships remained even when accounting...
TABLE 3 | Group differences for comorbid disorders by past-year non-medical opioid use status.

| Depression | Anxiety | PTSD | Alcohol | Marijuana | Stimulant | Sedative |
|------------|---------|------|---------|-----------|-----------|----------|
| No PY non-medical opioid use (n = 113) | 37.3 (41) | 38.9 (43)* | 23.2 (26)* | 10.8 (12) | 12.4 (14)* | 12.4 (14)* | 1.8 (2)* |
| PY non-medical opioid use, before tx (n = 29) | 44.8 (13) | 62.1 (18) | 20.7 (6) | 34.5 (10)* | 44.8 (13)* | 13.8 (4) |
| PY non-medical opioid use, while in tx (n = 68) | 45.6 (31) | 57.4 (39) | 19.1 (13) | 23.5 (16) | 45.6 (31) b | 14.7 (10) b |
| Total sample | 41.1 (85) | 48.1 (100) | 33.7 (70) | 14.9 (31) | 19.0 (40) | 27.6 (58) | 7.6 (16) |

Table footnote: PY, past-year; tx, treatment. Variables not in model did meet alpha threshold (p < 0.05).

*Adjusted Standardized Residual (ASR) = ≤ 2.

**Adjusted Standardized Residual (ASR) = ≥ 2.

TABLE 4 | Multivariable regressions of comorbid disorders.

| Variable | Anxiety | PTSD | Marijuana | Stimulant | Sedative |
|----------|---------|------|-----------|-----------|----------|
| PY non-medical opioid use, before tx | B = 0.737, p = 0.113 | B = 1.478, p = 0.033* | B = 1.024, p = 0.056 | B = 1.373, p = 0.006** | B = 1.912, p = 0.042* |
| 95% CI = 0.84–5.20 | 95% CI = 1.67–11.52 | 95% CI = 0.97–7.96 | 95% CI = 1.50–10.42 | 95% CI = 1.07–42.75 |
| PY non-medical opioid use, while in tx | B = 0.603, p = 0.072 | B = 0.372, p = 0.314 | B = 0.588, p = 0.169 | B = 1.572, p < .001*** | B = 2.116, p = 0.012* |
| 95% CI = 0.95–3.53 | 95% CI = 0.70–2.99 | 95% CI = 0.78–4.17 | 95% CI = 2.24–10.38 | 95% CI = 1.61–42.88 |
| Age | Not in model | B = −0.059, p = 0.003* | Not in model | Not in model | Not in model |
| | 95% CI = 0.91–0.98 | | | | |
| Female gender identity | B = 0.644, p = 0.038* | Not in model | B = −0.455, p = 0.634 | Not in model | Not in model |
| 95% CI = 1.04–3.50 | 95% CI = 0.30–1.33 | | | |
| High school degree or equivalent | Not in model | Not in model | Not in model | Not in model | B = −1.458, p = 0.012* |
| | | | | 95% CI = 0.07–0.73 |
| Non-Hispanic White race/ethnicity | Not in model | Not in model | Not in model | Not in model | Excluded from analysis a |
| Rural community | Not in model | Not in model | B = 0.608, p = 0.478 | Not in model | Not in model |
| | 95% CI = 0.72–4.69 | 95% CI = 0.72–4.69 | | |
| Fentanyl use | B = 0.209, p = 0.541 | B = 0.121, p = 0.753 | Not in model | B = −0.019, p = 0.963 | B = 0.544, p = 0.525 |
| 95% CI = 0.63–2.41 | 95% CI = 0.53–2.40 | | 95% CI = 0.45–2.16 | 95% CI = 0.32–9.25 |
| Injection preference | Not in model | Not in model | Not in model | Not in model | B = −0.147, p = 0.801 |
| | | | | 95% CI = 0.37–3.64 |
| Opioid use consequences | B = 0.067, p = 0.074 | B = 0.112, p = 0.009** | B = 0.020, p = 0.663 | B = 0.110, p = 0.019* | B = 0.146, p = 0.111 |
| 95% CI = 0.99–1.15 | 95% CI = 1.03–1.22 | 95% CI = 0.93–1.12 | 95% CI = 1.02–0.23 | 95% CI = 0.97–1.39 |
| Model metrics | $\chi^2$ (5) = 16.931 | $\chi^2$ (5) = 39.991 | $\chi^2$ (6) = 8.736 | $\chi^2$ (4) = 34.324 | $\chi^2$ (8) = 25.126 |
| $R^2$ = 0.105, p = 0.005 | $R^2$ = 0.243, p < .001 | $R^2$ = 0.069, p = 0.120 | $R^2$ = 0.222, p < .001 | $R^2$ = 0.271, p < .001 |

Table footnote: *p < 0.05.

**p < 0.01.

***p < 0.001.

PY, past-year; tx, treatment. Variables not in model did meet alpha threshold (p < 0.20, two-tailed) in bivariate analyses of comorbid psychiatric disorders. No PY non-medical opioid use was the reference group for PY non-medical opioid use, before tx and PY non-medical opioid use, while in tx.

Race/ethnicity variable was excluded from the sedative use disorder model analysis due to perfect separation (100% of patients with sedative use disorder reported Non-Hispanic White race/ethnicity). All $R^2$ were Nagelkerke $R^2$ Square values.

for other demographic and opioid use characteristics, as past-year non-medical opioid use was the variable most consistently associated with comorbid disorders in multivariable analyses. This relationship was strongest for PTSD, stimulant use disorder, and sedative use disorder.

One other opioid use characteristic, opioid use consequences, was associated with an increased likelihood of having comorbid disorders. In bivariate analyses, a greater number of consequences was associated with higher rates for anxiety, PTSD, stimulant use disorder, and sedative use disorder, though in multivariable analyses, significant associations only remained for PTSD and stimulant use disorder. This finding extends prior work demonstrating that a greater accumulation of opioid use consequences increases the likelihood of comorbid affective disorders.
disorder symptoms among people who regularly use heroin in a large urban area in the same state as this study (34). Injection use preference was not related to comorbid disorder status, despite prior research demonstrating an association between injection use and comorbid affective and substance use disorders among participants in large urban areas (35, 36). Similarly, fentanyl use was not related to comorbid disorders. Our analysis may highlight that even though fentanyl penetration to the drug supply and comorbidity are key contributors to overdose risk among Medicaid beneficiaries (37), in this geographic setting, the relationship of fentanyl use and comorbidity may be better understood as an interactive (vs. probabilistic) relationship. With regard to demographic characteristics, few relationships were observed. Younger age, lower educational attainment, and female gender were associated with a greater likelihood of PTSD, stimulant use disorder, and anxiety, respectively. Comorbid disorder status was unrelated to race/ethnicity in this sample. Similarly, rates did not differ for patients from rural areas compared to those residing in the small urban area where the OTP is located, suggesting that comorbid disorders among rural and small urban patients may be more similar than different.

The findings from this study highlight a few clinical implications. First, we suggest treatment authorities require OTPs to use validated screening tools for comorbid disorders, going a step further than current federal guidelines (9, 10). Second, we recommend that capacity and planning for coordinated care, particularly for affective disorders, be built into existing intake procedures. These strategies might include providing co-located services for affective disorders (15), developing partnerships for mental health service provision that build in accommodations for people living in small urban and rural areas (38), or evaluating the efficacy of evidence-based approaches for affective disorders, such as the Unified Protocol or Acceptance and Commitment Therapy (39, 40), when implemented through telehealth or adapted as computer-delivered interventions. Regardless of the strategy to assess and coordinate care, approaches should emphasize feasible innovations that mitigate implementation barriers and present financially sustainable changes at OTPs to facilitate adoption in a complex treatment system. The use of mixed methods implementation science protocols, such as NIATx (41), adapted to OTP settings in small urban and rural settings, may be a promising strategy to identify a more comprehensive understanding of patient and provider experiences as a means of improving and sustaining innovations to existing care models. This may be especially important at treatment intake, given that nearly all patients (e.g., transfers excluded), initiate methadone treatment following recent and ongoing non-medical opioid use, a robust correlate of affective disorder comorbidity in this sample. Third, we recommend future research that examines whether routinely screening patients (e.g., during clinical sessions and/or through short message services) engaged in long-term treatment for recent non-medical opioid use is feasible and improves linkage to care for comorbid disorders. Findings may provide support for the one-item measure presented here as a more efficient and less invasive method than current protocols (e.g., urine drug screens). Last, polysubstance use of stimulants and opioids has been rising nationally, and is a key determinant in the fourth wave of the opioid overdose crisis (42). While this study didn’t directly assess polysubstance use, the high rates of comorbid stimulant use disorder in this sample of OUD patients suggests polysubstance use is occurring for a sizable portion of patients, who urgently need integrated approaches that can reduce overdose-related harm.

This study has limitations. First, the sample was a convenience sample with a heterogeneous length of care for their current treatment episode. While this does introduce important differences, many studies examine recent non-medical opioid use without inquiring about treatment engagement. Furthermore, we sought to counteract this heterogeneity and aid clinical interpretation by providing comorbid disorder rates within sub-samples categorized by past-year non-medical opioid use status. Second, we did not assess all possible comorbid affective and substance use disorders, in part due to time constraints to gather info on disorders with low base rates (e.g., schizophrenia, hallucinogen use disorder). Similarly, we did not assess addictions not commonly addressed at OTPs (e.g., tobacco use disorder, gambling disorder), nor did we assess comorbid health conditions, such as infectious diseases, that overlap with OUD (43), and represent other important avenues where integrated approaches improve treatment outcomes (44). Future studies should investigate a full spectrum of OUD-related comorbidities, which ostensibly would highlight an even higher comorbidity burden and need for integrated approaches than this analysis. Third, our sample, while innovative in many ways (small urban and rural setting, public insurance homogeneity), was not powered to conduct an in-depth comparison of racial differences or population-specific comorbidity patterns (e.g., comorbid disorder rates among Black/African American patients), which may have provided valuable information about health disparities. Future research should gather data in small urban and/or rural settings where there is a greater representation of Medicaid/Medicare beneficiaries from diverse racial groups (e.g., Black/African Americans in the Deep South, Hispanic/Latinos in the American Southwest, and Native Americans in the Great Plains) who are receiving methadone treatment. Last, our comorbid affective disorder screening measures, while using established administration instructions and timelines, did not assess whether the patient would’ve screened positive at other time points in the past-year. As a result, our analysis may underestimate the rates of affective disorders compared to other studies (3, 45).

In conclusion, this study highlights a high rate of comorbid disorders, especially affective disorders, among publicly-insured methadone patients from small urban and rural areas. This burden is especially high for patients reporting recent non-medical opioid use, regardless of whether that use occurred before or during their current methadone treatment episode. Innovative and feasible approaches that assess patients for comorbid disorders and recent non-medical opioid use are needed to improve care coordination. We encourage local and federal treatment authorities, OTP directors, and methadone treatment researchers to consider our findings when developing screening, implementation, and coordinated care strategies.
DATA AVAILABILITY STATEMENT

The dataset presented in this article are not readily available because participants of this study did not agree for their data to be shared publicly, so supporting data is not available. Requests to access the dataset should be directed to JL (jlisterr@ssw.rutgers.edu), SR (stella@wayne.edu), and EA (ad2634@wayne.edu).

ETHICS STATEMENT

This study involved human participants and was reviewed and approved by the Wayne State University Institutional Review Board. Participants read an information sheet prior to participating in this study. Written informed consent was not required, as a waiver of documentation was obtained.

AUTHOR CONTRIBUTIONS

JL, GL, JE, EP, and SR: led writing, conceptualization, and methodology. JL and JE: oversaw data analyses. GL: led data analyses. EA and SR: provided reviews. All authors contributed to the article and approved the submitted version.

FUNDING

Data collection was supported by funds from the Substance Abuse and Mental Health Services Administration to the Michigan Department of Health and Human Services under Grant T080228 (to EA). Funds from a Wayne State University School of Social Work Research Enhancement Program (to JL) supported pilot data, feasibility analysis, and clinic partnerships that informed study design.

ACKNOWLEDGMENTS

The authors would like to acknowledge the opioid treatment program staff for assisting with the study design and recruitment, and the Substance Use Research Team at Wayne State University for coordinating data collection and data management activities.

REFERENCES

1. Rosic T, Naji L, Bawor M, Dennis BB, Plater C, Marsh DC, et al. The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study. *Neuropsychiatr Dis Treat.* (2017) 13:1399–408. doi: 10.2147/NDT.S129480
2. Teoh Bing Fei J, Yee A, Habil MH. Psychiatric comorbidity among patients on methadone maintenance therapy and its influence on quality of life. *Am J Addict.* (2016) 25:49–55. doi: 10.1111/ajad.12317
3. Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. *Drug Alcohol Depend.* (2019) 197:78–82. doi: 10.1016/j.drugalcdep.2018.12.030
4. Levine AR, Lundahl LH, Greenwald MK. Gender-specific predictors of retention and opioid abstinence during methadone maintenance treatment. *J Subst Abuse Treat.* (2015) 54:37–43. doi: 10.1016/j.jsat.2015.01.009
5. King VL, Kidorf MS, Stoller KB, Carter JA, Brooner RK. Influence of antisocial personality subtypes on drug abuse treatment response. *J Nerv Ment Dis.* (2001) 189:593–601. doi: 10.1097/00005053-200109000-00004
6. Ngo HT, Tait RJ, Hulse GK. Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naloxone implant or methadone maintenance. *J Psychopharmacol.* (2011) 25:774–82. doi: 10.1177/0269881110364266
7. Keen C, Kinner SA, Young JT, Jang K, Gan W, Samji H, et al. Prevalence of co-occurring mental illness and substance use disorder and association with overdose: a linked data cohort study among residents of British Columbia, Canada. *Addiction.* (2022) 117:129–40. doi: 10.1111/add.15580
8. Kampman K, Jarvis M. American society of addiction medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. *J Addict Med.* (2015) 9:358–67. doi: 10.1097/ADM.0000000000000166
9. CFR. Medication Assisted Treatment for Opioid Use Disorders. Title 42, Chapter I, Subchapter A, Part 8. College Park, MD: National Archives and Records Administration. Available online at: https://www.ecfr.gov/current/title-42/chapter-i/subchapter-a/part-8.8#part-8.8 (accessed February 4, 2022).
10. SAMHSA. Federal Guidelines for Opioid Treatment Programs. HHS Publication No. (SMA) XX-XXXX. Rockville, MD: Substance Abuse and Mental Health Services Administration (2015).
11. SAMHSA. Substance Use Disorder Treatment for People With Co-Occurring Disorders. Treatment Improvement Protocol (TIP) Series, No. 42. SAMHSA Publication No. PEP20-02-01-004. Rockville, MD: Substance Abuse and Mental Health Services Administration (2020).
12. Ledgerwood DM, Lister JJ, LaLiberte B, Lundahl LH, Greenwald MK. Injection opioid use as a predictor of treatment outcomes among methadone-maintained opioid-dependent patients. *Addict Behav.* (2019) 90:191–95. doi: 10.1016/j.addbeh.2018.10.046
13. Lister JJ, Weaver A, Ellis JD, Hinkle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. *Am J Drug Alcohol Abuse.* (2020) 46:273–86. doi: 10.1080/00952990.2019.1694536
14. Priester MA, Browne T, Iachini A, Clone S, DeHart D, Seay KD. Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: an integrative literature review. *J Subst Abuse Treat.* (2016) 61:47–59. doi: 10.1016/j.jsat.2015.09.006
15. Brooner RK, Kidorf MS, King VL, Peirce J, Neufeld K, Stoller K, et al. Managing psychiatric comorbidity within versus outside of methadone treatment settings: a randomized and controlled evaluation. *Addiction.* (2013) 108:1942–51. doi: 10.1111/add.12269
16. King VL, Brooner RK, Peirce J, Kolodner K, Kidorf M. Challenges and outcomes of parallel care for patients with co-occurring psychiatric disorder in methadone maintenance treatment. *J Dual Diagnosis.* (2014) 10:66–7. doi: 10.1080/15504263.2014.906132
17. Amiri S, McDonell MG, Denney JT, Buchwald D, Amram O. Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a US nationwide small area analysis. *Value Health.* (2021) 24:188–95. doi: 10.1016/j.jval.2020.08.2098
18. Joudrey PJ, Edelman EJ, Wang EA. Methadone for opioid use disorder—decades of effectiveness but still miles away in the US. *JAMA Psychiatry.* (2020) 77:1105–6. doi: 10.1001/jamapsychiatry.2020.1511
19. Yang JC, Roman-Urestarazu A, Brayne C. Responses among substance abuse treatment providers to the opioid epidemic in the USA: variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16. *PLoS ONE.* (2020) 15:e0229787. doi: 10.1371/journal.pone.0229787
20. Peterson C, Liu Y, Xu L, Nataraj N, Zhang K, Mikosz CA, et al. national 90-day readmissions after opioid overdose discharge. *Am J Prev Med.* (2019) 56:875–81. doi: 10.1016/j.amepre.2018.12.003
21. Economic Research Service. *Documentation: Rural-Urban Continuum Codes.* Washington, DC: US Department of Agriculture (USDA) (2020). Available
online at: https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/ (accessed February 4, 2022).

22. HRSA. Documentation: Federal Office of Rural Health Policy (FORHP) Data Files. Bethesda, MD: Health Resources & Services Administration (2021). Available online at: https://www.rural-health.gov/about-us/definition/datafiles.html (accessed February 4, 2022).

23. Pasman E, Agius E, Victor G, Broman M, Ray B, Resko S. Willingness to use syringe service programs and safe consumption sites among methadone patients with histories of injection drug use in a small Midwest community. Addict Res Theory. (2021) 1–7. doi: 10.1080/16066359.2021.1961759. [Epub ahead of print].

24. Wollschlaeger BA, Willson TM, Montejano LB, Ronquest NA, Nadipelli VR. Characteristics and treatment patterns of US commercially insured and medicaid patients with opioid dependence or abuse. J Opioid Manag. (2017) 13:207–20. doi: 10.5055/jom.2017.0389

25. Goldsmith HF, Puskin DS, Stiles DJ. Improving the Operational Definition of “Rural Areas” for Federal Programs. Rockville, MD: Federal Office of Rural Health Policy (1993).

26. Moses TE, Woodcock EA, Lister JJ, Lundahl LH, Greenwald MK. Developing a scale of domains of negative consequences of chronic heroin use. Addict Behav. (2018) 77:260–6. doi: 10.1016/j.addbeh.2017.07.027

27. Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale of domains of negative consequences of chronic heroin use. Addict Behav. (2018) 77:260–6. doi: 10.1016/j.addbeh.2017.07.027

28. Prins A, Bovin MJ, Smolenski DJ, Marx BP, Kimerling R, Jenkins-Guarnieri MA, et al. The Primary Care PTSD screen for DSM-5 (PC-PTSD-5): development and evaluation within a veteran primary care sample. J Gen Intern Med. (2016) 31:1206–11. doi: 10.1007/s11606-016-3703-5

29. Gossop M, Darke S, Griffiths P, Handje J, Powis B, Hall W, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. (1995) 90:607–14. doi: 10.1046/j.1360-0443.1995.9056072.x

30. Hides L, Dawe S, Young RM, Kavanagh DJ. The reliability and validity of the Severity of Dependence Scale for detecting cannabis dependence in psychosis. Addiction. (2007) 102:35–40. doi: 10.1111/j.1360-0443.2006.01669.x

31. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. (1998) 158:1789–95. doi: 10.1001/archinte.158.16.1789

32. Little RJA, A. test of missing completely at random for multivariate data with missing values. J Am Stat Assoc. (1988) 83:1198–202. doi: 10.1080/01621459.1988.10478722

33. Haberman SJ. The analysis of residuals in cross-classified tables. Biometrics. (1973) 29:205–20. doi: 10.2307/2529686

34. Reid HH, Lundahl LH, Lister JJ, Woodcock EA, Greenwald MK. Mediational pathways among trait impulsivity, heroin-use consequences, and current mood state. Addict Res Theory. (2018) 26:421–9. doi: 10.1080/16066359.2018.1435513

35. Dinwiddie SH, Cotterl L, Compton W, Abdallah AB. Psychopathology and HIV risk behaviors among injection drug users in and out of treatment. Drug Alcohol Depend. (1996) 43:1–11. doi: 10.1016/S0376-8716(96)01290-2

36. Fischer B, Manzoni P, Rehm J. Comparing injecting and non-injecting illicit opioid users in a multisite Canadian sample (OPICAN Cohort). Eur Addict Res. (2006) 12:230–9. doi: 10.1159/000094425

37. Crystal S, Nowels M, Olsson M, Samples H, Williams AR, Treitler P. Medically treated opioid overdoses among New Jersey medicaid beneficiaries: rapid growth and complex comorbidity amid growing fentanyl penetration. J Subs Abuse Treat. (2021) 131:108546. doi: 10.1016/j.jsat.2021.108546

38. Guerrero AP, Balon R, Beresin EV, Louie AK, Coverdale JH, Brenner A, et al. Rural mental health training: an emerging imperative to address health disparities. Acad Psychiatry. (2019) 43:1–5. doi: 10.1007/s40596-018-1012-5

39. Barlow DH, Harris BA, Eustis EH, Farchione TJ. The unified protocol for transdiagnostic treatment of emotional disorders. World Psychiatry. (2020) 19:245–6. doi: 10.1002/wps.20748

40. Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. Acceptance and commitment therapy: model, processes and outcomes. Behav Res Ther. (2006) 44:1–25. doi: 10.1016/j.brat.2005.06.006

41. Ford JH, Osborne EL, Assefa MT, McIvaine AM, King AM, Campbell K, et al. Using NIAaT strategies to implement integrated services in routine care: a study protocol. BMC Health Serv Res. (2018) 18:431. doi: 10.1186/s12913-018-3241-4

42. Ciccarone D. The rise of illicit fentanyl, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. (2021) 34:344–50. doi: 10.1097/YCO.0000000000000717

43. Kolla BP, Oesterle T, Gold M, Southwick F, Rummans T. Infectious diseases occurring in the context of substance use disorders: a concise review. J Neurol Sci. (2020) 411:116719. doi: 10.1016/j.jns.2020.116719

44. McNamara KF, Biondi BE, Hernández-Ramírez RU, Taweh N, Grimsaw AA, Springer SA. A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. Open Forum Infect Dis. (2021) 8:ofab289. doi: 10.1093/ofid/ofab289

45. Tormohlen KN, Mojtahib R, Seiwell A, McGinty EE, Stuart EA, Tobin KE, et al. Co-occurring opioid use and depressive disorders: patient characteristics and co-occurring health conditions. J Dual Diagnosis. (2021) 17:296–303. doi: 10.1080/15504263.2021.1979349

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lister, Lee, Ellis, Pasman, Agius and Resko. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.